Get the Stockscreener App
40.68
5.89%
-2.56
Agios Pharmaceuticals Inc stock is traded at $40.68, with a volume of 422.67K.
It is down -5.89% in the last 24 hours and up +0.48% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$43.24
Open:
$42.86
24h Volume:
422.67K
Relative Volume:
0.57
Market Cap:
$2.36B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.581
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
-5.54%
1M Performance:
+0.48%
6M Performance:
+35.20%
1Y Performance:
-9.30%
1-Day Range:
$40.47
$44.10
1-Week Range:
$40.18
$44.10
52-Week Range:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
40.70 | 2.52B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.80 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.61 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.11 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil marketsRecession Risk & Safe Capital Investment Plans - newser.com
Agios (AGIO) Unveils Promising Mitapivat Data at ASH 2025 - GuruFocus
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition - The Manila Times
What data driven models say about Agios Pharmaceuticals Inc.’s futureEarnings Summary Report & Community Driven Trade Alerts - newser.com
Agios (Nasdaq: AGIO) shows mitapivat data: 77.8% alpha-thal response; 30.5-week mean - Stock Titan
Is Agios Pharmaceuticals Inc. (8AP) stock a top dividend aristocrat candidateJuly 2025 Breakouts & AI Optimized Trade Strategies - newser.com
Will Agios Pharmaceuticals Inc. benefit from macro trendsJuly 2025 Volume & Fast Gaining Stock Reports - newser.com
How supply chain issues affect Agios Pharmaceuticals Inc. stockJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - newser.com
Is Agios Pharmaceuticals Inc. building a consolidation basePortfolio Risk Report & AI Driven Stock Movement Reports - newser.com
What is HC Wainwright's Estimate for AGIO FY2025 Earnings? - MarketBeat
What earnings revisions data tells us about Agios Pharmaceuticals Inc.Entry Point & Smart Investment Allocation Insights - newser.com
Is it time to cut losses on Agios Pharmaceuticals Inc.Inflation Watch & Breakout Confirmation Alerts - newser.com
Can Agios Pharmaceuticals Inc. stock deliver sustainable ROERate Hike & Daily Stock Trend Reports - newser.com
What drives Agios Pharmaceuticals Inc stock priceMarket Capitalization Trends & High Return Capital Strategies - earlytimes.in
Is Agios Pharmaceuticals Inc. (8AP) stock among top earnings playsMarket Volume Summary & Safe Capital Growth Trade Ideas - newser.com
Is Agios Pharmaceuticals Inc. stock supported by strong cash flowsStop Loss & Weekly High Return Opportunities - newser.com
Institutional scanner results for Agios Pharmaceuticals Inc.Bond Market & Weekly Chart Analysis and Trade Guides - newser.com
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Savvy Advisors Inc. Takes Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Published on: 2025-11-02 02:45:06 - newser.com
Candlestick signals on Agios Pharmaceuticals Inc. stock todayQuarterly Market Summary & Reliable Price Action Trade Plans - newser.com
Agios Pharmaceuticals Q3 2025 Earnings Preview - MSN
Agios outlines Q4 2025 PYRUKYND milestones and anticipates U.S. thalassemia approval amid global expansion - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2025 Earnings Call Transcript - Insider Monkey
RBC Capital Keeps Their Buy Rating on Agios Pharma (AGIO) - The Globe and Mail
Published on: 2025-11-01 04:26:21 - newser.com
Agios Pharmaceuticals’ Earnings Call: Growth and Challenges - MSN
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues - sharewise.com
Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
High Growth Tech Stocks In The US Market With Promising Potential - simplywall.st
Can Agios Pharmaceuticals Inc. stock surprise with earnings upsideGap Down & Comprehensive Market Scan Reports - newser.com
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer |
Oct 27 '25 |
Option Exercise |
25.01 |
3,302 |
82,583 |
65,029 |
| Gheuens Sarah | Chief Medical Officer |
Oct 27 '25 |
Sale |
43.92 |
3,302 |
145,024 |
61,727 |
0.29%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):